Compare FLL & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | EDSA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 51.5M |
| IPO Year | 2014 | 2018 |
| Metric | FLL | EDSA |
|---|---|---|
| Price | $1.11 | $2.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.00 | ★ $16.33 |
| AVG Volume (30 Days) | ★ 241.1K | 37.8K |
| Earning Date | 11-05-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $302,376,000.00 | N/A |
| Revenue This Year | $3.39 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.53 | N/A |
| 52 Week Low | $1.01 | $0.72 |
| 52 Week High | $3.37 | $20.32 |
| Indicator | FLL | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 20.19 | 24.59 |
| Support Level | N/A | $0.83 |
| Resistance Level | $2.74 | $4.27 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 10.07 | 0.00 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.